Karyopharm’s Phase III Trial Delivers Mixed Results in Myelofibrosis

Karyopharm Therapeutics reported mixed outcomes from its Phase III SENTRY trial evaluating Xpovio (selinexor) in combination with ruxolitinib for treating myelofibrosis, a rare blood cancer. While the study achieved one co-primary endpoint, it failed to meet the second, raising concerns among investors.

The combination therapy significantly improved spleen size reduction, with 50% of patients achieving a ≥35% reduction at 24 weeks compared to 28% with ruxolitinib alone. However, improvements in symptom scores were similar across both groups and did not reach statistical significance.

Additional findings showed encouraging trends in overall survival and early signals of disease modification, though other endpoints such as progression-free survival showed no notable differences.

Despite the mixed results, the treatment demonstrated a manageable safety profile. Karyopharm plans to engage with regulators and present further data, as the need for more effective therapies in myelofibrosis remains significant.

30-03-2026